Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2025 · 10-Q
Revenue$29.20M$29.20Mno prior Q2 2024 on file Net Income$1.53M$1.53MN/M vs Q2 2024 EPS Diluted$0.08$0.08N/M vs Q2 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$4,561,000+483.2% Free Cash Flowderived$4,551,000+517.5% Margins · derivedGross margin63.8%
Operating margin11.0%
Net margin5.2%
ended Jun 30, 2025 · filed Aug 8, 2025 · 39 d after period end